Treating influenza

This trial has been cancelled. Clinical trials may be cancelled prior to commencement, or during the course of the trial, for a number of reasons – these may be summarised below. You cannot enrol in this trial.

About this trial

This trial  is looking at people with fluA highly contagious and relatively common viral infection of the respiratory system, transmitted by infected droplets of moisture which may be spread through coughing and sneezing. Most people with flu recover but some go on to develop secondary infections such as pneumonia which may be fatal. who also have HIV or another immune compromising condition. Participants will be treated with either a combination of three drugs or just one drug .

Investigators will be looking at a number of things including how long people show the symptoms of flu, how many develop a resistantHIV which has mutated and is less susceptible to the effects of one or more anti-HIV drugs is said to be resistant. strain[HIV strain] Any subgroup of the HIV species. Because HIV mutates very easily, there are many different strains (and may be multiple strains within a single person). of flu and any side effects of treatment.

Update: The study was terminated due to poor enrollment.

Official title:

A Randomized Open Label Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Amantadine and Ribavirin With Oseltamivir Versus Oseltamivir to Influenza A Virus Infected Immunocompromised Subjects

What is this trial studying?

other – experimental treatments

Start date:

September 2009 (This may be the proposed or expected start date for trials which have not yet started.)

How many participants will this trial enrol?

250 (The exact number of participants may be lower or slightly higher than this. Some trials also have specific quotas for participants from each state, city or clinic.)

How long is this trial planned to go for?

Participants in this trial will be asked to follow the trial protocol for 20 days. Following the conclusion of the trial, participants will be followed up for a further 190 days.

Links to further information:

• http://clinicaltrials.gov/ct2/show/study/NCT00979251?term=HIV&recr=Open&cond=HIV&cntry1=PA%3AAU&rank=23&show_locs=Y#locn

Who can enrol in this trial?

You may be eligible to participate in this trial if you meet the following criteria:

• At least 1 years old
• Confirmed influenza A

This is a summary of key inclusion and exclusion criteria for this trial. There may be other criteria which may exclude some people from participation in this trial. Some laboratory tests may also be required. Consult your doctor, or view the trial protocol or informed consent documentation to see the full range of exclusion and inclusion criteria.

Disclaimer

While NAPWA has taken every care to compile the information on this page and to keep it up-to-date, we cannot guarantee its correctness and completeness.

Before making the decision to participate in any clinical research, visit the NAPWA website for background information on participating in clinical research.

Contact NAPWA if you have any questions or comments about this trial.